Tagged With Allergan

A lawsuit claims a major breast implant maker knew its implants were likely causing cancer, and hid the complaints using fake company names


Two women have filed a class-action lawsuit against a major breast implant maker after hundreds of Americans developed a rare cancer linked to implants


Dispensed: Pharma's next big megamerger, a string of healthcare IPOs, and why the CEO of Clover Health regrets setting up shop in Silicon Valley



Allergan spikes 30% after AbbVie agrees to buy the Botox-maker for $63 billion


Abbvie is buying Allergan in a $63 billion pharma mega-deal


A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.



Botox is made from the deadliest toxin on earth. Then we started injecting it in our faces.


Allergan is asking millennials if they're 'bo-curious,' and it's part of a plan to find a new generation of Botox customers


Stanford researchers are figuring out how ketamine fights depression — and why the drug has been called 'the most important discovery in half a century'


The FDA just rejected Allergan's women's health drug


David Tepper has gone full activist on healthcare giant Allergan


Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here's how the Botox-maker fell out grace with investors and then became a takeover target.



A 'breakthrough' depression drug inspired by ketamine is attracting more attention from big pharma


Allergan is selling off 2 of its non-core businesses in a bid to appease frustrated investors


The FDA just approved a new kind of medication that could change the way migraine patients are treated


Investors are frustrated with Botox-maker Allergan -- and its CEO says it's 'deep into the process' of figuring out what to do next



Sydney biotech Elastagen has just been bought for $120 million by the maker of Botox


Allergan just got one step closer to approval for its migraine drug -- and it's part of a wave of new treatments for the condition that affects 38 million Americans


MORGAN STANLEY: Here are the 10 healthcare companies most likely to get bought this year


The Bill Ackman problem everyone forgot is now at threat-level substantial